Overview

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Status:
Completed

Trial end date:
2016-07-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy is safety and tolerable when administered to patients with locally advanced or metastatic bladder cancer and to gain preliminary data on whether patients may benefit from this combination.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

PharmaBio Development Inc.

Treatments:

Cisplatin
Gemcitabine